Poster #01048

i i f r - r r i

Pseudomonas aeruginosa fr i i i i r i

S rri , if r .S r i , i i r , ri ir
JMI Laboratories, North Liberty, IA, USA

Introduction

- Meropenem-vaborbactam (MVB) is a combination of a carbapenem and a carbapenemase inhibitor developed to inhibit serine carbapenemases, such as KPC.
- MVB is approved in Europe for the treatment of complicated urinary tract infection (cUTI), including acute pyelonephritis, complicated intra-abdominal infection (cIAI), hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), and bacteremia (BSI) associated with any of the infections listed above.
- This study examined the activity of MVB and comparators against *P. a a* collected from patients hospitalized with pneumonia in Europe during 2016–2020.
- Isolates from patients in the intensive care unit (ICU) and those with VAP were analysed as subsets, as were Eastern vs. Western European isolates.

Results

P a a a was the most common Gram-negative pathogen isolated from patients hospitalized with pneumonia for all patients, ICU patients, and patients with VAP (Figure 1).

- The susceptibilities of meropenem-vaborbactam and its comparators against [illegible]

Dee Shortridge
JMI Laboratories
345 Beaver Kreek Centre, Suite A
North Liberty, Iowa 52317
Phone: 319-665-3370
Email: dee-shortridge@jmilabs.com

To obtain a PDF of this poster:
Scan the QR code or visit https://www.jmilabs.com/data/posters/ECCMID2021_MeroVaborVEuroPneumonia.pdf
Charges may apply. No personal information is stored.